Most “market access” teams are playing defense. The winners sell before the clock runs out.
In pharma, timing isn’t a detail—it’s the business model.
If you’re a commercial market access vendor (or you support one), the biggest strategic mistake is wai…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Company (and Your Timeline)
In pharma, “almost ready” can be the most expensive place to be.
You’ve got a promising label, a manufacturing plan, and a launch calendar that’s been st…

Pharma M&A has a blind spot—and it’s costing companies real money.
Most pharma buyers obsess over clinical data, manufacturing capacity, and competitive positioning. But when it comes to Paragraph IV filings, many teams treat them like background…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma leader, investor, or in-house counsel, you’ve probably seen the same comforting assumption play out across decks and diligence memos:…

Drug patent expiry isn’t just a legal milestone—it’s a commercial calendar.
If you’re in pharma, biotech, or medtech, you already know the headline: patents expire, exclusivity erodes, and competition moves in. But the real question is whether your o…

Sell the line before the patent breaks: a business development playbook for solid-dose equipment suppliers
The most expensive mistake in pharma equipment sales isn’t pricing—it’s timing.
By the time a patent cliff becomes headline news, the buying deci…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The “Smarter Monopoly” Debate Is Here—and It’s About Orphan Drugs
There’s a quiet but consequential shift happening in how the U.S. protects medicines—and it’s forcing policymakers, investors, and patients to ask a hard question: Are we rewarding innov…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The biggest mistake in biologics business development isn’t pricing. It’s timing.
If you wait until a biologic’s Loss of Exclusivity (LOE)…

Generic competition is supposed to be the finish line. But in pharma, it’s often just the starting pistol.
For years, the industry has sold a simple story: patents expire, generics arrive, prices fall, patients benefit. Yet the reality is messier—and i…